<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39247398</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2213-4220</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Integrative medicine research</Title><ISOAbbreviation>Integr Med Res</ISOAbbreviation></Journal><ArticleTitle>Effectiveness and safety of Liriope Tuber (Liriopis seu Ophiopogonis Tuber, Maidong) included traditional herbal medicine for patients with paroxysmal atrial fibrillation: A systematic review, meta-analysis, and network analysis.</ArticleTitle><Pagination><StartPage>101069</StartPage><MedlinePgn>101069</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101069</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.imr.2024.101069</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Conventional medicine (CM) for paroxysmal atrial fibrillation (PAF) have limitations and side effects. Integrative approaches, including traditional herbal medicines like Liriope Tuber, are being explored for potential benefits, although evidence remains limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In April 2023, a literature search was conducted across nine databases, focusing on randomized controlled trials assessing the effects of Liriope Tuber in traditional herbal medicine (LTHM) on PAF. The risk of bias was evaluated using Version 2 of the Cochrane risk-of-bias tool for randomized trials. A random-effects model was employed for the meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 43 studies with 3,743 participants were included. The meta-analysis indicated that adding LTHM to CM reduced PAF frequency (SMD = -0.99, 95 % CI = -1.40 to -0.57, I² = 88 %, <i>N</i> = 16, <i>n</i> = 1266), left atrium diameter (LAD) (MD = -2.39 mm, 95 % CI = -3.09 to -1.68), P-wave dispersion (Pd) (MD = -6.41 ms, 95 % CI = -8.44 to -4.37), high sensitive C-Reactive Protein (hs-CRP) (MD = -1.10 mg/l, 95 % CI = -1.73 to -0.47), and improved left ventricular ejection fraction (LVEF) (MD = 4.71 %, 95 % CI = 3.17 to 6.25). Thirty-four studies raised concerns about bias, with eight showing high risk. Certainty of evidence was rated as "low" for PAF frequency, LAD, Pd, hs-CRP, and LVEF.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">LTHM combined with CM may reduce PAF frequency. However, due to the complexity of interventions, with Liriope Tuber being only one component of the regimen, high risk of bias, substantial heterogeneity, and indirectness, interpretations should be cautious.</AbstractText><AbstractText Label="STUDY REGISTRATION" NlmCategory="UNASSIGNED">PROSPERO (ID: CRD42023477926).</AbstractText><CopyrightInformation>© 2024 Korea Institute of Oriental Medicine. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Hanbit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Diagnostics, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Sukjong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Convergence Technology for food industry, Graduate School of Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Dasol</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Diagnostics, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mun</LastName><ForeName>Yeun-Ja</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center of Traditional Korean, Medicine, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leem</LastName><ForeName>Jungtae</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Diagnostics, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center of Traditional Korean, Medicine, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Integr Med Res</MedlineTA><NlmUniqueID>101612707</NlmUniqueID><ISSNLinking>2213-4220</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">East Asian traditional medicine</Keyword><Keyword MajorTopicYN="N">Liriope Tuber</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Paroxysmal atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39247398</ArticleId><ArticleId IdType="pmc">PMC11378115</ArticleId><ArticleId IdType="doi">10.1016/j.imr.2024.101069</ArticleId><ArticleId IdType="pii">S2213-4220(24)00049-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsao C.W., Aday A.W., Almarzooq Z.I., et al. Heart Disease and Stroke Statistics-2022 Update: a Report From the American Heart Association. Circulation. 2022;145(8):e153–e639. doi: 10.1161/CIR.0000000000001052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001052</ArticleId><ArticleId IdType="pubmed">35078371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C.E., Wang K.L., Lip G.Y.H. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014;111(5):789–797. doi: 10.1160/TH13-11-0948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH13-11-0948</ArticleId><ArticleId IdType="pubmed">24500243</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart S., Hart C.L., Hole D.J., McMurray J.J.V. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359–364. doi: 10.1016/s0002-9343(02)01236-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9343(02)01236-6</ArticleId><ArticleId IdType="pubmed">12401529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988. doi: 10.1161/01.str.22.8.983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.22.8.983</ArticleId><ArticleId IdType="pubmed">1866765</ArticleId></ArticleIdList></Reference><Reference><Citation>Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med. 1995;98(5):476–484. doi: 10.1016/S0002-9343(99)80348-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(99)80348-9</ArticleId><ArticleId IdType="pubmed">7733127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Yang P.S., Jang E., et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart. 2018;104(24):2010–2017. doi: 10.1136/heartjnl-2017-312930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2017-312930</ArticleId><ArticleId IdType="pubmed">29666179</ArticleId></ArticleIdList></Reference><Reference><Citation>January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014;130(23):2071–2104. doi: 10.1161/CIR.0000000000000040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000040</ArticleId><ArticleId IdType="pubmed">24682348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T., Yamashita T., Sagara K., Iinuma H., Fu L.T. Progressive nature of paroxysmal atrial fibrillation. Published online 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15170094</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade J.G., Champagne J., Dubuc M., et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation. 2019;140(22):1779–1788. doi: 10.1161/CIRCULATIONAHA.119.042622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.042622</ArticleId><ArticleId IdType="pubmed">31630538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotecha D., Holmes J., Krum H., et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235–2243. doi: 10.1016/S0140-6736(14)61373-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61373-8</ArticleId><ArticleId IdType="pubmed">25193873</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–2677. doi: 10.1056/NEJMoa0708789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0708789</ArticleId><ArticleId IdType="pubmed">18565859</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–1833. doi: 10.1056/NEJMoa021328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa021328</ArticleId><ArticleId IdType="pubmed">12466506</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–1840. doi: 10.1056/NEJMoa021375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa021375</ArticleId><ArticleId IdType="pubmed">12466507</ArticleId></ArticleIdList></Reference><Reference><Citation>Opolski G., Torbicki A., Kosior D.A., et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126(2):476–486. doi: 10.1378/chest.126.2.476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.126.2.476</ArticleId><ArticleId IdType="pubmed">15302734</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khatib S.M., Allen LaPointe N.M., Chatterjee R., et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014;160(11):760–773. doi: 10.7326/M13-1467.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M13-1467</ArticleId><ArticleId IdType="pubmed">24887617</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S., Sardar P., Lichstein E., Mukherjee D., Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013;36(1):122–133. doi: 10.1111/j.1540-8159.2012.03513.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1540-8159.2012.03513.x</ArticleId><ArticleId IdType="pubmed">22978656</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat A., Khanna S., Chen H.H.L., et al. Integrated care in atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021;14(3) doi: 10.1161/CIRCOUTCOMES.120.007411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.120.007411</ArticleId><ArticleId IdType="pmc">PMC7982130</ArticleId><ArticleId IdType="pubmed">33663224</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher C., Elliott A.D., Wong C.X., et al. Integrated care in atrial fibrillation: a systematic review and meta-analysis. Heart. 2017;103(24):1947–1953. doi: 10.1136/heartjnl-2016-310952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2016-310952</ArticleId><ArticleId IdType="pubmed">28490616</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Liao J., Yao K., Jiang W., Wang J. Application of traditional Chinese medicine in treatment of atrial fibrillation. Evid Based Complement Alternat Med. 2017 doi: 10.1155/2017/1381732. 2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/1381732</ArticleId><ArticleId IdType="pmc">PMC5294366</ArticleId><ArticleId IdType="pubmed">28243308</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Nie S., Gao H., et al. The effects of wenxin keli on p-wave dispersion and maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2013 doi: 10.1155/2013/245958. 2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/245958</ArticleId><ArticleId IdType="pmc">PMC3867920</ArticleId><ArticleId IdType="pubmed">24368925</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y., Tang Y., Huang L., He P. Systematic review and meta-analysis on efficacy of traditional Chinese medicine for atrial fibrillation through cluster analysis. Ann Palliat Med. 2021;10(8):8982–8990. doi: 10.21037/apm-21-1785.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-21-1785</ArticleId><ArticleId IdType="pubmed">34488385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Tang Z., Peng X., et al. Network meta-analysis: aspirin plus traditional Chinese medicine for stroke prevention in patients with atrial fibrillation. J Herb Med. 2020;22 doi: 10.1016/j.hermed.2020.100355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hermed.2020.100355</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., Luo Y., Wang X., et al. Investigating the efficiency and tolerability of traditional Chinese formulas combined with antiarrhythmic agents for paroxysmal atrial fibrillation: a systematic review and Bayesian network meta-analysis. Phytomedicine. 2022;94 doi: 10.1016/j.phymed.2021.153832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2021.153832</ArticleId><ArticleId IdType="pubmed">34781230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Tang Z., Zhu W., Ge L., Ge J. Efficacy and safety of traditional Chinese medicine on thromboembolic events in patients with atrial fibrillation: a systematic review and meta-analysis. Complement Ther Med. 2017;32:1–10. doi: 10.1016/j.ctim.2017.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctim.2017.03.006</ArticleId><ArticleId IdType="pubmed">28619293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wei B., Wang J., et al. Shensongyangxin capsules for paroxysmal atrial fibrillation: a systematic review of randomized clinical trials. PLoS ONE. 2016;11(3) doi: 10.1371/journal.pone.0151880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0151880</ArticleId><ArticleId IdType="pmc">PMC4801382</ArticleId><ArticleId IdType="pubmed">26999010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon S., Jin C., Cho S.Y., et al. Paeoniae Radix-containing herbal medicine for patients with restless legs syndrome: a systematic review and meta-analysis. Complement Ther Clin Pract. 2019;35:329–341. doi: 10.1016/j.ctcp.2019.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctcp.2019.03.015</ArticleId><ArticleId IdType="pubmed">31003678</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Y.M., Sun L., Lu C., et al. Benefits of herbal formulae containing Poria cocos (Fuling) for type 2 diabetes mellitus: a systematic review and meta-analysis. PLoS ONE. 2022;17(12) doi: 10.1371/journal.pone.0278536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0278536</ArticleId><ArticleId IdType="pmc">PMC9714931</ArticleId><ArticleId IdType="pubmed">36455062</ArticleId></ArticleIdList></Reference><Reference><Citation>Astragalus-containing Chinese herbal medicine combined with chemotherapy for cervical cancer: a systematic review and meta-analysis - PubMed. Accessed July 5, 2023. https://pubmed.ncbi.nlm.nih.gov/34393766/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361476</ArticleId><ArticleId IdType="pubmed">34393766</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeyun An.  Wonkwang University; 2022. The Effect of Herbal Medicine On Arrhythmia: Systematic Review and Meta-Analysis of Randomized Control Clinical Trial.http://www.riss.kr/link?id=T16377364</Citation></Reference><Reference><Citation>Chungyeol Lee. Effects of ginseng radix and Ophiopogonis tuber on field potentials in rat hippocampal and cardiac muscle slices. J Physiol Pathol Korean Med. 2003;17(6):1463–1467.</Citation></Reference><Reference><Citation>Li N., Zhang J.Y., Zeng K.W., Zhang L., Che Y.Y., Tu P.F. Anti-inflammatory homoisoflavonoids from the tuberous roots of Ophiopogon japonicus. Fitoterapia. 2012;83(6):1042–1045. doi: 10.1016/j.fitote.2012.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fitote.2012.05.011</ArticleId><ArticleId IdType="pubmed">22626747</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X.L., Xing F.W. Ethnobotanical study on medicinal plants around Mt.Yinggeling, Hainan Island, China. J Ethnopharmacol. 2009;124(2):197–210. doi: 10.1016/j.jep.2009.04.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2009.04.042</ArticleId><ArticleId IdType="pubmed">19409476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M.H., Chen X.J., Wang M., Lin L.G., Wang Y.T. Ophiopogon japonicus–A phytochemical, ethnomedicinal and pharmacological review. J Ethnopharmacol. 2016;181:193–213. doi: 10.1016/j.jep.2016.01.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2016.01.037</ArticleId><ArticleId IdType="pubmed">26826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane handbook for systematic reviews of interventions. Accessed July 3, 2023. https://training.cochrane.org/handbook/current</Citation></Reference><Reference><Citation>Sterne J.A.C., Sutton A.J., Ioannidis J.P.A., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. doi: 10.1136/bmj.d4002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d4002</ArticleId><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–996. doi: 10.1016/j.jclinepi.2007.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2007.11.010</ArticleId><ArticleId IdType="pubmed">18538991</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26(25):4544–4562. doi: 10.1002/sim.2889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2889</ArticleId><ArticleId IdType="pubmed">17476644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Q. The effect of Shen Song Yangxin capsule combined with amiodarone in the treatment of atrial fibrillation and Detection and analysis of related indexes (应用参松养心胶囊联合胺碘酮方案对阵发性房颤的治疗作用及相关指标检测分析) Contemp Med. 2018;24(32):134–136.</Citation></Reference><Reference><Citation>Huang Y., Zhang Z., Chen R., Ding Y., Chen M., Zhu Y. Effects of Dingji formula on inflammatory factors and myocardial fibrosis in paroxysmal atrial fibrillation(定悸方对阵发性房颤炎症因子及心肌纤维化影响). Inaugural Meeting of the Chinese Society of Traditional Chinese Medicine Branch of Family Medicine and 2016 Academic Annual Meeting.:8.</Citation></Reference><Reference><Citation>Li F., Kuang P., Chen Y., Liu K. Effect of Shensongyangxin capsules combined with amiodarone on MMP-2 and hs-CRP of patients with paroxysmal atrial fibrillation(参松养心胶囊联合胺碘酮治疗对阵发性房颤患者血清MMP-2,hs-CRP水平的影响) Internal Med. 2016;11(05):694–697.</Citation></Reference><Reference><Citation>Ma M., Hao W. Clinical research on effects of filling weakness and fasting Ben, Expelling Phlegm and removing blood stasis on c-reactive protein in patients with paroxysmal atrial fibrillation (补虚固本,祛痰化瘀法对阵发性房纤颤患者血浆C-反应蛋白影响的临床研究) West J Tradit Chin Med. 2011;24(09):1–3.</Citation></Reference><Reference><Citation>Shi T., Yao Z., Qin Z., Ding B., Dai Y., Yao X. Identification of absorbed constituents and metabolites in rat plasma after oral administration of Shen-Song-Yang-Xin using ultra-performance liquid chromatography combined with quadrupole time-of-flight mass spectrometry. Biomed Chromatogr. 2015;29(9):1440–1452. doi: 10.1002/bmc.3443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bmc.3443</ArticleId><ArticleId IdType="pubmed">25708105</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg J.Z., Day A., Brinkworth G.D., et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021;372:m4743. doi: 10.1136/bmj.m4743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4743</ArticleId><ArticleId IdType="pmc">PMC7804828</ArticleId><ArticleId IdType="pubmed">33441384</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.S., Siddiqi T.J., Butler J., et al. Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial. ESC Heart Fail. 2021;8(2):872–878. doi: 10.1002/ehf2.13273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13273</ArticleId><ArticleId IdType="pmc">PMC8006711</ArticleId><ArticleId IdType="pubmed">33619896</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Saenz de Tejada M., Bilbao A., Ansola L., et al. Responsiveness and minimal clinically important difference of the Minnesota living with heart failure questionnaire. Health Qual Life Outcomes. 2019;17(1):36. doi: 10.1186/s12955-019-1104-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-019-1104-2</ArticleId><ArticleId IdType="pmc">PMC6376687</ArticleId><ArticleId IdType="pubmed">30764842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., You W., Wang N., et al. Ophiopogonin D increases SERCA2a interaction with Phospholamban by promoting CYP2J3 upregulation. Oxid Med Cell Longev. 2020;2020 doi: 10.1155/2020/8857906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8857906</ArticleId><ArticleId IdType="pmc">PMC7790559</ArticleId><ArticleId IdType="pubmed">33488937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao J., Wang H., Zhou H., Li S. The saponin monomer of dwarf lilyturf tuber, DT-13, reduces L-type calcium currents during hypoxia in adult rat ventricular myocytes. Life Sci. 2005;77(24):3021–3030. doi: 10.1016/j.lfs.2005.01.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2005.01.039</ArticleId><ArticleId IdType="pubmed">15978637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Jung-chul, Oh Sung-won, Song Chang-Hoon, Lee Seul-hee, Jeong Jong-jin, Sun Seung-ho. case report of Chengsim Yeunja-Tang(CYT) for atrial fibrillation with cerebral-infarction. J Korean Orient Internal Med. 2006;27(3):752–762.</Citation></Reference><Reference><Citation>Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa612</ArticleId><ArticleId IdType="pubmed">32860505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof P., Auricchio A., Bax J., et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German atrial fibrillation competence NETwork and the European Heart Rhythm Association. Europace. 2007;9(11):1006–1023. doi: 10.1093/europace/eum191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eum191</ArticleId><ArticleId IdType="pubmed">17897925</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz K.F., Altman D.G., Moher D., Group CONSORT. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi: 10.1136/bmj.c332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c332</ArticleId><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian Z., Liu B., Moher D., et al. Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: current situation and future development. Front Med. 2011;5(2):171–177. doi: 10.1007/s11684-011-0132-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-011-0132-z</ArticleId><ArticleId IdType="pubmed">21695622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnier J.J., Boon H., Rochon P., et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006;144(5):364–367. doi: 10.7326/0003-4819-144-5-200603070-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-144-5-200603070-00013</ArticleId><ArticleId IdType="pubmed">16520478</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., He X., Yan Z., Zhang D. Influence of Jianxin PinglüPill on BNP and ALD levels in patients with paroxysmal atrial fibrillation(健心平律丸对阵发性房颤患者BNP,Ald的影响) Chin J Integr Med Cardio Cerebrovasc Dis. 2014;12(07):782–784.</Citation></Reference><Reference><Citation>He X., Yan Z., Zhang D., Bi Y., Chen Y. Effect of Jianxin Pingrong pill on cardiac remodeling in patients with paroxysmal atrial fibrillation(健心平律丸对阵发性心房颤动患者心脏重构的影响) J N Chin Med. 2014;46(07):30–31.</Citation></Reference><Reference><Citation>Chen Y., He X., Yan Z., Zhang D. Effect of Jianxin PinglüPill on HS-CRP in paroxysmal atrial fibrillation(健心平律丸治疗阵发性房颤的临床疗效及对hs-CRP的影响) Chin J Integr Med Cardio Cerebrovasc Dis. 2014;12(03):271–272.</Citation></Reference><Reference><Citation>Cui F. Clinical effect of Guizhi Fuling pill on paroxysmal atrial fibrillation of kidney deficiency and blood stasis type(桂枝茯苓丸加减治疗肾虚血瘀型阵发性房颤的临床疗效研究). Thesis. 2021.</Citation></Reference><Reference><Citation>Pan J., Qiao Y., Yang J. Clinical resaerch of evaluating the influences of Shensong Yangxin capsule on the left atrial function of patients with paroxysmal atrial fibrillation based on the technology of two-dimensional speckle tracking imaging(基于二维斑点追踪成像技术探讨参松养心胶囊对阵发房颤患者左心房功能影响的临床研究) Tianjin J Tradit Chin Med. 2019;36(10):959–962.</Citation></Reference><Reference><Citation>Zhang B. Clinical study of compound Guanbaifu in the treatment on paroxysmal atrial fibrillation(复方关白附治疗阵发性心房颤动的临床研究). Thesis. 2019.</Citation></Reference><Reference><Citation>Wu W., Liu C. Clinical observation on the treatment of paroxysmal atrial fibrillation with Qi and Yin deficiency type by combining compound Guanbaifu Decoxtion with metoprolol succinate extended-release tablets(复方关白附汤联合琥珀酸美托洛尔缓释片治疗气阴两虚型阵发性房颤的临床观察) Chin Naturopath. 2022;30(07):83–86.</Citation></Reference><Reference><Citation>Jiao Q., He X., Yan Z. Efficacy of amiodarone combined with Jianxin Pingrong pill in the treatment of paroxysmal atrial fibrillation and its effect on serum MMP-2 and LAD(胺碘酮联合健心平律丸治疗阵发性房颤的疗效及对血清MMP-2和LAD的影响) Guid J Tradit Chin Med Pharma. 2018;24(24):118–119.</Citation></Reference><Reference><Citation>Luo X. Clinical study on treating paroxysmal atrial fibrillation with broth of Yangxinxifeng(养心熄风汤治疗阵发性房颤的临床研究). Thesis. 2013.</Citation></Reference><Reference><Citation>Ying L., Liu H., Zhu Y. Clinical study on the treatment of hypertension combined with paroxysmal atrial fibrillation by Yangxin Dingji capsule combined with irbesartan(养心定悸胶囊联合厄贝沙坦治疗高血压合并阵发性心房颤动的临床研究) Chin J Integr Med Cardio Cerebrovasc Dis. 2021;19(13):2222–2225.</Citation></Reference><Reference><Citation>Liu S., Zhao Y. Clinical observation on supplementing Qi and nourishing Yin therapy for treatment of paroxysmal atrial fibrillation with deficiency syndrome of Qi and Yin(益气养阴法治疗阵发性房颤气阴亏虚证的疗效观察) Chin J Integr Med Cardio Cerebrovasc Dis. 2015;13(18):2047–2048.</Citation></Reference><Reference><Citation>Chen T., Chang Z., Fan X., Du B. Effect of Zhigancao decoction combined with amiodarone on paroxysmal atrial fibrillation and atrial remodeling (炙甘草汤联合胺碘酮治疗阵发性心房颤动及对心房重构的影响) China Modern Doctor. 2017;55(15):118–121.</Citation></Reference><Reference><Citation>Luo Q. Efficacy observation of 54 cases of paroxysmal atrial fibrillation treated with Chuchan decoction(自拟除颤汤治疗阵发性心房颤动54例疗效观察) Yunnan J Tradit Chin Med Mater Med. 2009;30(06):34–35.</Citation></Reference><Reference><Citation>Mou A. Clinical observation of Ningxinanshen decoction in the treatment of paroxysmal atrial fibrillation(Qi and Yin Deficiency) with Type 2 diabetes Mellitus(宁心安神方治疗阵发性房颤(气阴两虚型)合并2型糖尿病患者的临床疗效观察). Thesis. 2021.</Citation></Reference><Reference><Citation>Liu J., Liao Y., Tang Y. Effect of Dingxin capsule combined with metoprolol on P-wave dispersion and serum inflammatory factors in patients with paroxysmal atrial fibrillation(定心颗粒联合美托洛尔对阵发性心房颤动患者P波离散度及血清炎症因子的影响) Modern J Integr Tradit Chin West Med. 2017;26(23):2564–2566.</Citation></Reference><Reference><Citation>Ge R., Li J., Xu J., Li M. Study on prevention of early recurrence of Xiaju Huayu capsule after radiofrequency ablation of paroxysmal atrial fibrillation(夏橘化瘀胶囊对预防阵发性房颤射频消融术后早期复发的研究) Syst Med. 2022;7(19):1–5.</Citation></Reference><Reference><Citation>Fan X. Study on the efficacy of losartan combined with amiodarone and Shensong Yangxin capsule in the treatment of hypertension with paroxysmal atrial fibrillation(氯沙坦联合胺碘酮与参松养心胶囊治疗高血压伴阵发性心房颤动的疗效研究) For all Health. 2015;9(12):167.</Citation></Reference><Reference><Citation>Jin Y. Effects of metoprolol and Shensongyangxin capsule on P wave dispersion and high sensitivity C-reactive protein in patients with paroxysmal atrial fibrillation(美托洛尔联合参松养心胶囊对阵发性心房颤动患者P波离散度和血浆高敏C-反应蛋白的影响) Chin Circ J. 2012;27(5):353–356.</Citation></Reference><Reference><Citation>Wu P., Yu H., Guo D., et al. Therapeutic effects of Betaloc combined with Shensong Yangxin capsule on P wave dispersion in patients with paroxysmal atrial fibrillation(倍他乐克联合参松养心胶囊对阵发性房颤患者P波离散度的影响) Chin J Difficult Complic Cases. 2007;(05):270–272.</Citation></Reference><Reference><Citation>Tang Y., Liu M., Li J. Observations on the effect of usual care combined with Shensong Yangxin capsule in treating atrial fibrillation in the elderly(常规加参松养心胶囊治疗老年房颤效果观察) People's Milit Surg. 2012;55(01):41–42.</Citation></Reference><Reference><Citation>Shao J. Clinical efficacy of rosuvastatin combined with Shensong Yangxin capsule in the treatment of paroxysmal atrial fibrillation in elderly coronary heart disease(瑞舒伐他汀联合参松养心胶囊治疗老年冠心病阵发性心房纤颤的临床疗效观察) Guide Chin Med. 2013;11(24):141–142.</Citation></Reference><Reference><Citation>Pan J., Qiao Y., Yang J. Clinical observation on the influence of Shensong Yangxin capsules on left atrial structural remodeling in patients with paroxysmal atrial fibrillation(参松养心胶囊对阵发房颤患者左房结构重构的影响) Guangming J Chin Med. 2021;36(03):389–392.</Citation></Reference><Reference><Citation>Lu J. Clinical observation on the effect of Shensong Yangxin capsule on P-wave dispersion in patients with paroxysmal atrial fibrillation(参松养心胶囊对阵发性房颤患者P波离散度影响的临床观察) Prevent Treatment Cardio Cerebr Vascular Dis. 2012;12(02):134–136.</Citation></Reference><Reference><Citation>Han Y., Xue R., Zhang X. Effect of Shensong Yangxin capsule on the frequency of paroxysmal atrial fibrillation episodes(参松养心胶囊对阵发性心房颤动发作频率的影响) Chin J Misdiagnos. 2010;10(28):6827–6828.</Citation></Reference><Reference><Citation>Liu Y., Miao L., Sun Q. Clinical study of Shensong Yangxin Capsule combined bisoprolol on elderly paroxysmal atrial fibrillation(参松养心胶囊联合比索洛尔治疗老年阵发性心房颤动) J Changchun Univ Chin Med. 2020;36(04):688–691.</Citation></Reference><Reference><Citation>Chen S., You C., Huang M., Cheng X., Zheng J., Huang Q. Clinical study on the treatment of paroxysmal atrial fibrillation combined with cardiac insufficiency by Shensong Yangxin capsule combined with sacubitril valsartan(参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并心功能不全的临床研究) Chin J Integr Medic Cardio Cerebrovasc Dis. 2022;20(01):131–134.</Citation></Reference><Reference><Citation>Liu Y., Liu Z., Zhang X., Ban Y., Sun Z. Efficacy of Shensong Yangxin capsule combined with amiodarone in the treatment of paroxysmal atrial fibrillation(参松养心胶囊联合胺碘酮治疗阵发性心房纤颤的疗效观察) Hebei Med J. 2010;32(19):2716–2717.</Citation></Reference><Reference><Citation>Li S., Chang Y., Wu Z. Effect of Shensong Yangxin capsule in the adjuvant treatment of heart failure combined with paroxysmal atrial fibrillation in the elderly and its effect on patients’ cardiac function(参松养心胶囊辅助治疗老年心力衰竭合并阵发性房颤的效果及对患者心功能的影响) Clin Res. 2019;27(08):137–138.</Citation></Reference><Reference><Citation>Xiao J., Fu J., Li X., Ji D., Chen J. Analysis of the safety and clinical effects of Shensong Yangxin capsules in treating hypertension complicated with paroxysmal atrial fibrillation(参松养心胶囊治疗高血压并发阵发性房颤的临床疗效及安全性分析) West J Tradit Chin Med. 2021;34(08):110–112.</Citation></Reference><Reference><Citation>Cao D., Yang X., Shi Y. Clinical observation on 58 cases of chronic heart failure combined with paroxysmal atrial fibrillation treated with Shensong Yangxin capsule(参松养心胶囊治疗慢性心力衰竭合并阵发性心房纤颤58例临床观察) Chin J Clin Rational Drug Use. 2013;6(17):49–50.</Citation></Reference><Reference><Citation>Sheng H., Xu M. The clinical observation on ShenSong YangXin capsule in treating paroxysmal atrial firbrillation(参松养心胶囊治疗阵发性心房颤动30例) Gansu J Tradit Chin Med. 2010;23(12):24–25.</Citation></Reference><Reference><Citation>Men R. Treatment of paroxysmal atrial fibrillation with Shensong Yangxin capsule in 42 cases(参松养心胶囊治疗阵发性心房颤动42例) China Pharmaceuticals. 2012;21(17):69.</Citation></Reference><Reference><Citation>Wang A., Pu J., Yong Q., et al. A multicenter clinical study on the treatment of paroxysmal atrial fibrillation with Shensong Yangxin Capsule(参松养心胶囊治疗阵发性心房颤动的多中心临床研究) National Med J Chin. 2011;(24):1677–1681.</Citation></Reference><Reference><Citation>Han H., Zhou Y., Wang Y., Pan Y., Xu C. Clinical study on the therapeutic effect of Shensong Yangxin capsule on paroxysmal atrial fibrillation(参松养心胶囊治疗阵发性心房颤动的临床研究) Chin J Difficult Complicat Cases. 2007;(07):389–391.</Citation></Reference><Reference><Citation>Liu Y., Li S. The effect of Shensong Yangxin capsule and amiodarone on p-wave dispersion in patients with paroxysmal atrial fibrillation with coronary artery disease(参松养心胶囊及乙胺碘肤酮对冠心病阵发性房颤病人P波离散度的影响) Heilongjiang Medicine Journal. 2013;26(03):408–409.</Citation></Reference><Reference><Citation>Peng G., Li S., Liu B., Zhang W. Effect of Shensong Yangxin Capsuleon P-wave dispersion in patients with hypertension and paroxysmal atrial fibrillation(参松养心胶囊对高血压并阵发性心房颤动患者P波离散度的影响) Chin J Integr Med Cardio Cerebrovasc Dis. 2012;10(01):29–31.</Citation></Reference><Reference><Citation>Kang X., Huang X., Zheng Z. Combined with western medicine treatment of paroxysmal atrial fibrillation randomized parallel group study Shensongyangxin Capsules(参松养心胶囊联合西药治疗阵发性心房纤颤随机平行对照研究) J Pract Tradit Chin Internal Med. 2014;28(12):72–74.</Citation></Reference><Reference><Citation>Liu H., Zhang J. Treatment of paroxysmal atrial fibrillation with Shensong Yangxin capsule in 60 cases(参松养心胶囊治疗阵发性心房颤动60例) Shaanxi J Tradit Chin Med. 2011;32(11):1509–1510.</Citation></Reference><Reference><Citation>Zhou Q. Effect of valsartan combined with Shen Song Yangxin capsule in the treatment of hypertensive patients with atrial fibrillation(缬沙坦联合参松养心胶囊治疗高血压合并心房颤动的效果) Chin J Thrombos Hemostas. 2018;24(02):257–260.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>